In vitro studies with CD33 and dNPM1 simultaneously expressing OCI-AML cell lines demonstrated that CAR’TCR-T cells were more effective in killing the tumor cells compared to CAR-T cells and TCR-T cells applied separately. This evidence concerns the gene CD33 and acute myeloid leukemia.